These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21351094)

  • 21. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
    Kuwana M; Shirai Y; Takeuchi T
    J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum KL-6 concentrations are associated with molecular sizes and efflux behavior of KL-6/MUC1 in healthy subjects.
    Shigemura M; Konno S; Nasuhara Y; Shijubo N; Shimizu C; Nishimura M
    Clin Chim Acta; 2013 Sep; 424():148-52. PubMed ID: 23778023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
    J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.
    Wang Z; Cai M; Weng Y; Zhang F; Meng D; Song J; Zhou H; Xie Z
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1353-61. PubMed ID: 25544672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.
    Graziano SL; Tatum AH; Gonchoroff NJ; Newman NB; Kohman LJ
    Clin Cancer Res; 1997 Jan; 3(1):87-93. PubMed ID: 9815542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.
    Schmidt LH; Kuemmel A; Schliemann C; Schulze A; Humberg J; Mohr M; Görlich D; Hartmann W; Bröckling S; Marra A; Hillejan L; Goletz S; Karsten U; Berdel WE; Spieker T; Wiewrodt R
    Lung Cancer; 2016 Feb; 92():8-14. PubMed ID: 26775589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
    Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
    Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.
    Hirasawa Y; Kohno N; Yokoyama A; Kondo K; Hiwada K; Miyake M
    Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):589-94. PubMed ID: 10673204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis.
    Shigemura M; Nasuhara Y; Konno S; Shimizu C; Matsuno K; Yamguchi E; Nishimura M
    J Transl Med; 2012 Jul; 10():111. PubMed ID: 22650152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional and clinical characterization of the putative tumor suppressor WWOX in non-small cell lung cancer.
    Becker S; Markova B; Wiewrodt R; Hoffarth S; Hähnel PS; Pleiner S; Schmidt LH; Breitenbuecher F; Schuler M
    J Thorac Oncol; 2011 Dec; 6(12):1976-83. PubMed ID: 21892104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of serum KL-6 as a prognostic marker in pulmonary tuberculosis patients.
    Miwa S; Suzuki Y; Shirai M; Ohba H; Kanai M; Eifuku T; Suda T; Hayakawa H; Chida K
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):240-2. PubMed ID: 23228506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease.
    Wang J; Huang Z; Xue M; Huang H; Zheng X; Zhong N; Sun B
    J Clin Lab Anal; 2020 Feb; 34(2):e23070. PubMed ID: 31691368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
    Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
    Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
    Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
    J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
    Ishikawa N; Hattori N; Yokoyama A; Kohno N
    Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.
    Wang J; Ling L; Chen S; Chou L; Wang Y; Hu L
    Lab Med; 2024 May; 55(3):271-276. PubMed ID: 37566516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.